Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. [electronic resource]
Producer: 20200916ISSN:- 2379-3708
- Animals
- CRISPR-Cas Systems
- Carcinoma, Pancreatic Ductal -- metabolism
- Disease Models, Animal
- Dynamins -- antagonists & inhibitors
- Enzyme Inhibitors -- pharmacology
- GTP Phosphohydrolases -- genetics
- Leflunomide -- pharmacology
- Mice
- Mice, Knockout
- Mitochondria -- metabolism
- Mitochondrial Dynamics -- drug effects
- Mitophagy -- drug effects
- Oxidative Phosphorylation -- drug effects
- Pancreatic Neoplasms -- metabolism
- Quinazolinones -- pharmacology
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Video-Audio Media
There are no comments on this title.
Log in to your account to post a comment.